ARC-1030 | 1106998-31-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: ARC-1030
• 英文别名: (2R)-6-amino-2-(6-{[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]formamido}hexanamido)hexanamide；(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-[6-[[(2R)-1,6-diamino-1-oxohexan-2-yl]amino]-6-oxohexyl]-3,4-dihydroxyoxolane-2-carboxamide
• CAS: 1106998-31-5
• 化学式: C₂₂H₃₅N₉O₆
• 分子量: 521.577
• InChiKey: XBZOZZWDQFYHMN-NKGQZSHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  37
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  247
• 氢给体数：
  7
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  ARC-1030 在 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成
  参考文献：
  名称：

  Structural Analysis of ARC-Type Inhibitor (ARC-1034) Binding to Protein Kinase A Catalytic Subunit and Rational Design of Bisubstrate Analogue Inhibitors of Basophilic Protein Kinases

  摘要：

  The crystal structure of a complex of the catalytic subunit (type alpha) of cAMP-dependent protein kinase (PKA C alpha) with ARC-type inhibitor (ARC-1034), the presumed lead scaffold of previously reported adenosine-oligo-arginine conjugate-based (ARC-type) inhibitors, was solved. Structural elements important for interaction with the kinase were established with specifically modified derivatives of the lead compound. On the basis of this knowledge, a new generation of inhibitors, conjugates of adenosine-4'-dehydroxymethyl-4'-carboxylic acid moiety and oligo(D-arginine), was developed with inhibitory constants well into the subnanomolar range. The structural determinants of selectivity of the new compounds were established in assays with ROCK-II and PKB gamma.

  DOI：

  10.1021/jm800797n
• 作为产物：
  描述：

  ARC-1014 在 三异丙基硅烷 、 三氟乙酸 作用下， 以 水 为溶剂， 反应 2.5h， 生成 ARC-1030
  参考文献：
  名称：

  Structural Analysis of ARC-Type Inhibitor (ARC-1034) Binding to Protein Kinase A Catalytic Subunit and Rational Design of Bisubstrate Analogue Inhibitors of Basophilic Protein Kinases

  摘要：

  The crystal structure of a complex of the catalytic subunit (type alpha) of cAMP-dependent protein kinase (PKA C alpha) with ARC-type inhibitor (ARC-1034), the presumed lead scaffold of previously reported adenosine-oligo-arginine conjugate-based (ARC-type) inhibitors, was solved. Structural elements important for interaction with the kinase were established with specifically modified derivatives of the lead compound. On the basis of this knowledge, a new generation of inhibitors, conjugates of adenosine-4'-dehydroxymethyl-4'-carboxylic acid moiety and oligo(D-arginine), was developed with inhibitory constants well into the subnanomolar range. The structural determinants of selectivity of the new compounds were established in assays with ROCK-II and PKB gamma.

  DOI：

  10.1021/jm800797n